SCHEMBL4673353

SCHEMBL4673353

O=C(C=C(O)c1nc[nH]n1)c1cc(Oc2ccccc2)co1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 4/20 0.33
RAB9A P51151 4/20 0.33
LMNA P02545 3/20 0.33
MAPT P10636 2/20 0.33
PKM P14618 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
CES1 P23141 1/20 0.33
GCK P35557 1/20 0.32
SMN1; SMN2 Q16637 4/20 0.32
POLB P06746 1/20 0.32
HSP90AA1 P07900 1/20 0.32
AKR1C3 P42330 1/20 0.31
HPGDS O60760 1/20 0.31
ERCC5 P28715 1/20 0.31
FEN1 P39748 1/20 0.31
TP53 P04637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671052 0.90 NR4A2 (0.33) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL4675663 0.90 CDH1 (0.38) KDM4ENPC1RAB9ALMNAMAPT
SCHEMBL4676171 0.90 PARP10 (0.33) ALDH1A1CYP3A4
SCHEMBL4675460 0.89 LMNA (0.35) KDM4ELMNACYP3A4
SCHEMBL4675372 0.89 LMNA (0.38) ALDH1A1KDM4ELMNAPOLBMEN1
SCHEMBL4673894 0.88 RAB9A (0.40) ALDH1A1NPC1RAB9ALMNAMAPT
SCHEMBL4677273 0.87 LTA4H (0.37) ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4673377 0.87 KMT2A (0.37) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL4675073 0.87 RAB9A (0.37) ALDH1A1KDM4ENPC1RAB9AMAPT
SCHEMBL4676486 0.87 KDM4E (0.39) ALDH1A1KDM4EMAPTPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ALDH1A1 980/4885KDM4E 947/4885NPC1 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.